認知症治療薬の考え方、使い方

出版社： 中外医学社
著者：
発行日： 2017-06-30
分野： 臨床医学：一般  >  薬物療法
ISBN： 9784498129887
シリーズ： 考え方、使い方シリーズ
電子書籍版： 2017-06-30 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,180 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,180 円(税込)

購入する

商品紹介

高齢者の認知症有病率が高まるにつれ、必ずしも認知症を専門としない非専門医が薬物療法を行う機会もより一層増えることが予想される。非薬物治療の解説は他書に譲り、本書では抗認知症薬、抗精神病薬、抗うつ薬、睡眠薬、抗不安薬、気分安定薬、漢方薬、排尿障害治療薬、高血圧治療薬など、認知症患者の診療に用いられる薬物療法に焦点を絞り、それらの処方の実際や注意点など医療従事者が知っておくべき必要知識を解説した。

目次

  • 認知症治療薬の考え方、使い方

    ―目次―

    Chapter I　認知症概説
    　1．認知症概説

    Chapter II　総論
    　1．抗認知症薬
    　2．抗精神病薬
    　3．抗うつ薬
    　4．睡眠薬，抗不安薬
    　5．気分安定薬（抗てんかん薬）
    　6．認知症の治療と漢方
    　7．排尿障害治療薬
    　8．高血圧治療薬

    Chapter III　各論
    　1．Alzheimer型認知症の治療
    　2．血管性認知症（VaD）
    　3．Lewy小体型認知症
    　4．前頭側頭葉変性症
    　5．進行性核上性麻痺，大脳皮質基底核変性症
    　6．せん妄

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Chapter I 認知症概説

P.10 掲載の参考文献
1) 日本神経学会 認知症疾患治療ガイドライン作成合同委員会. 認知症疾患治療ガイドライン 2010. 東京 : 医学書院 ; 2010.
 
2) 日本神経学会 認知症疾患治療ガイドライン作成合同委員会. 認知症疾患治療ガイドライン 2010 コンパクト版 2012. 東京 : 医学書院 ; 2012.
 
3) McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease : Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 ; 7 : 263-9.
PubMed
4) 高橋三郎, 大野裕監訳, 染矢俊幸他訳. DSM-5 精神疾患の診断・統計マニュアル. 東京 : 医学書院 ; 2014.
 
5) Sperling RA, Aisen PS, Laurel A, et al. Toward defining the preclinical stages of Alzheimer's disease : Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement. 2011 ; 7 : 280-92.
 
6) Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 ; 7 : 270-9.
 
7) 平成24年度厚生労働科学研究費補助金 (厚生労働科学特別研究事業) "認知症, 特にBPSDへの適切な薬物使用に関するガイドライン作成に関する研究" 班. かかりつけ医のためのBPSDに対する向精神薬使用ガイドライン. 2013.
 
8) 日本神経学会 認知症疾患ガイドライン作成合同委員会. 認知症疾患治療ガイドライン 2010 追補版. http://www.neurology-jp.org/guidelinem/degl/sinkei_degl_2010_cqvi-1.pdf
 

Chapter II 総論

P.31 掲載の参考文献
1) 厚生労働科学研究費補助金 創薬基盤研究推進事業 平成25年度 (2013年度) 国内基盤技術調査報告書. 神経疾患に関する医療ニーズ調査.
 
2) Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984 ; 141 : 1356-64.
PubMed
3) Panisset M, Roudier M, Saxton J, et al. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol. 1994 ; 51 : 41-5.
PubMed
4) Blesa R. Galantamine : therapeutic effects beyond cognition. Dement Geriatr Cogn Disord. 2000 ; 11 Suppl 1 : 28-34.
 
5) Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009 ; 80 : 600-7.
PubMed
6) Wattmo C, Paulsson E, Minthon L, et al. A longitudinal study of risk factors for community-based home help services in Alzheimer's disease : the influence of cholinesterase inhibitor therapy. Clin Interv Aging. 2013 ; 8 : 329-39.
PubMed
7) Nordstrom P, Religa D, Wimo A, et al. The use of cholinesterase inhibitors and the risk of myocardial infarction and death : a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J. 2013 ; 34 : 2585-91.
 
8) Hager K, Baseman AS, Nye JS, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. Neuropsychiatr Dis Treat. 2014 ; 10 : 391-401.
 
9) Bartus RT, Dean RL 3rd, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982 ; 217 : 408-17.
PubMed
10) Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia : loss of neurons in the basal forebrain. Science. 1982 ; 215 : 1237-9.
PubMed
11) Mori E, Ikeda M, Kosaka K, et al. Donepezil for dementia with Lewy bodies : a randomized, placebo-controlled trial. Ann Neurol. 2012 ; 72 : 41-52.
PubMed
12) Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001 ; 57 : 613-20.
 
13) Takata K, Kitamura Y, Saeki M, et al. Galantamine-induced amyloid-β clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem. 2010 ; 285 : 40180-91.
 
14) Herrmann N, Rabheru K, Wang J, et al. Galantamine treatment of problematic behavior in Alzheimer disease : post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry. 2005 ; 13 : 527-34.
PubMed
15) Mercier Fl, Lefevre G, Huang HL, et al. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin. 2007 ; 23 : 3199-204.
 
16) Winblad B, Grossberg G, Frolich L, et al. IDEAL : a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007 ; 69 (4 Suppl 1) : S14-22.
 
17) Bullock R, Bergman H, Touchon J, et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin. 2006 ; 22 : 483-94.
PubMed
18) Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology. 1999 ; 38 : 735-67.
PubMed
19) Parsons CG, Stoffler A, Danysz W. Memantine : a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology. 2007 ; 53 : 699-723.
PubMed
20) Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine : a pooled data analysis. Int J Geriatr Psychiatry. 2008 ; 23 : 537-45.
PubMed
21) Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil : a randomized controlled trial. JAMA. 2004 ; 291 : 317-24.
PubMed
22) Gardette V, Lapeyre-Mestre M, Piau A, et al. A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer's disease in Europe : predictors of discontinuation and switch in the ICTUS study. CNS Drugs. 2014 ; 28 : 157-70.
PubMed
23) Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease : a systematic review and meta-analysis. Clin Interv Aging. 2008 ; 3 : 211-25.
PubMed
24) 高橋長秀, 高橋昌義, 朱年亮, 他. ドネペジル治療で効果不十分であったAlzheimer型認知症に対するガランタミン臭化塩素酸塩の有効性および安全性の検討. 老年精神医学雑誌. 2014 ; 25 : 70-86.
 
25) Gauthier S, Emre M, Farlow MR, et al. Strategies for continued successful treatment of Alzheimer's disease : switching cholinesterase inhibitors. Curr Med Res Opin. 2003 ; 19 : 707-14.
 
26) Namioka N, Hanyu H, Hatanaka H, et al. Comprehensive geriatric assessment in elderly patients with dementia. Geriatr Gerontol Int. 2015 ; 15 : 27-33.
PubMed
27) 今井幸充. 痴呆性高齢者の在宅服薬管理と介護負担の関連について. 治療. 2005 ; 87 : 433-42.
Medical*Online
28) 櫻井博文, 羽生春夫. 服薬アドヒアランスをよくする工夫. 治療. 2015 ; 97 : 383-7.
Medical*Online
29) Watanabe N, Yamamura K, Suzuki Y, et al. Pharmacist-based Donepezil Outpatient Consultation Service to improve medication persistence. Patient Prefer Adherence. 2012 ; 6 : 605-11.
PubMed
30) 日本神経学会 認知症疾患治療ガイドライン作成合同委員会. 認知症疾患治療ガイドライン 2010. 東京 : 医学書院 ; 2010.
 
P.44 掲載の参考文献
1) 平成27年度厚生労働科学研究費補助金 (厚生労働科学特別研究事業) 認知症に対するかかりつけ医の向精神薬使用の適正化に関する調査研究班作成. かかりつけ医のためのBPSDに対応する向精神薬使用ガイドライン 第2版. 厚生労働省. 2015.
 
2) 千葉茂. 認知症における抗精神病薬の使い方. 老年精神医学雑誌. 2013 ; 24 : 756-62.
Medical*Online
3) Hatta K, Kishi Y, Wada K, et al. Antipsychotics for delirium in the general hospital setting in consecutive 2453 inpatients ; A prospective observational study. Int J Geriatr Psychiatry. 2014 ; 29 : 253-62.
PubMed
4) 工藤喬, 武田雅俊. 認知症の薬物療法 抗精神病薬. In : 日本認知症学会編. 認知症テキストブック. 東京 : 中外医学社 ; 2008. p.171-3.
 
5) Stephem M. Stahl. スタールのヴィジュアル薬理学 抗精神病薬の精神薬理 (田島治, 林建郎訳). 東京 : 星和書店 ; 2001. p.35-47, p.46-92.
 
6) Ballard C, Corbett A. Agitation and aggression in people with Alzheimer's disase. Curr Opin Psychiatry. 2013 ; 26 : 252-9.
 
7) 認知症ケア高度化推進事業. ひもときシートガイドライン改訂版. 認知症介護研究・研修センター. 2010.
 
8) 平成24年度厚生労働科学研究費補助金 (厚生労働科学特別研究事業) 認知症, 特にBPSDへの適切な薬物使用に関するガイドライン作成に関する研究班作成. かかりつけ医のためのBPSDに対応する向精神薬使用ガイドライン. 厚生労働省. 2012.
 
9) 国際老年精神医学会編, 日本老年精神医学会監訳. せん妄 : BPSDとの鑑別診断 (繁田雅弘監訳). 認知症の行動と心理症状BPSD. 東京 : アルタ出版 ; 2013 ; P.48-9, 125-8.
 
10) 高橋智. 認知症の行動・心理症状 (BPSD) を早期に発見するにはどうすればよいでしょうか. In : 中島健二, 和田健二編. 認知症診療 Q&A 92. 東京 : 中外医学社 ; 2012. p.26-8.
 
11) 日本総合病院精神医学会せん妄指針改定班. せん妄の臨床指針-せん妄の治療指針 第2版. 東京 : 星和書店 ; 2015.
 
12) 日本神経学会 認知症疾患治療ガイドライン作成合同委員会. 認知症疾患治療ガイドライン 2010 コンパクト版 2012. 東京 : 医学書院 ; 2012.
 
13) 角徳文. かかりつけ医のための向精神薬使用ガイドライン. In : 本間昭編. かかりつけ医のための認知症診療の実践. 大阪 : 医薬ジャーナル社 ; 2015.
 
P.62 掲載の参考文献
1) 国際老年精神医学会著, 日本老年精神医学会翻訳. BPSD痴呆の行動と心理症状. 東京 : アルタ出版 ; 2005.
 
2) 藤瀬昇. 脳器質性疾患によるうつ状態の特徴と対応. 臨床精神医学. 2013 ; 42 : 945-50.
Medical*Online
3) 佐藤晋璽, 水上勝義. 日常臨床に必要な認知症症候学. 池田学編著. 東京 : 新興医学出版 ; 2014. p.79-93.
 
4) Olin JT, Katz IR, Meyers BS, et al. Provisional diagnostic criteria for depression of Alzheimer disease : rationale and background. Am J Geriatr Psychiatry. 2002 ; 10 : 129-41.
PubMed
5) 楯林義孝. 認知症とうつ病. 老年精神医学雑誌. 2008 ; 19 : 414-9.
Medical*Online
6) 中込和幸. 抗うつ薬の分類と特徴 精神障害への対応の基礎知識. 日本医師会雑誌 生涯教育シリーズ 64. 2002 ; 131 : S85-7.
 
7) David A smith 著, 上田均, 酒井明夫監訳. 高齢者のための新しい向精神薬療法. 東京 : 星和書店 ; 2003.
 
8) 米本直裕, 稲垣正俊, 山田光彦. 12の抗うつ薬はどれも同じか? -マルチプルトリートメントメタアナリシスが開く新しいエビデンス. 臨床精神薬理. 2010 ; 13 : 1975-86.
 
9) Stephen M Stahl, 仙波純一, 他監訳. メディカル・サイエンス・インターナショナル ストール精神薬理学エッセンシャルズ 神経科学的基礎と応答. 第4版, 第7章 抗うつ薬. p.309-400.
 
10) Bauer M, Pfennig A, Severus E, et al. Behalf of the Task Force on Unipolar Depressive Disorders 著, 山田和男訳. 単極性うつ病の生物学的治療ガイドライン 第I部 : 大うつ病性障害の急性期と継続期の治療WFSBP (生物学的精神医学会世界連合) 版 2013年改訂版. 東京 : 星和書店 ; 2013.
 
11) Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with parokxetine in major depression J Clini Psychiatry. 2000 ; 61 : 656-63.
 
12) 古野拓. Escitalopramの基礎データと臨床試験成績. 臨床精神薬理. 2011 ; 14 : 1291-302.
 
13) 犬塚伸. 3. BPSDへの対応 (薬物治療を中心に). 第4章 認知症の治療と管理. In : 中島健二, 天野直二, 下濱俊他編. 認知症ハンドブック. 東京 : 医学書院 ; 2013. p.226-32.
 
P.74 掲載の参考文献
1) Urrestarazu E, Iriarte J. Clinical management of sleep disturbances in Alzheimer's disease : current and emerging strategies. Nat Sci Sleep. 2016 ; 8 : 21-33.
PubMed
2) Terzaghi M, Amaldi D, Rizzetti MC, et al. Analysis of video-polysomnographic sleep findings in dementia with Lewy bodies. Mov Disord. 2013 ; 28 : 1416-23.
 
3) Pao WC, Boeve BF, Ferman TJ, et al. Polysomnographic findings in dementia with Lewy bodies. Neurologist. 2013 ; 19 : 1-6.
 
4) 厚生労働科学研究費補助金・障害者対策総合研究事業「睡眠薬の適正使用および減量・中止のための診療ガイドラインに関する研究班」および日本睡眠学会・睡眠薬使用ガイドライン作成ワーキンググループ編. 睡眠薬の適正使用・休薬ガイドライン. 東京 : じほう ; 2013.
 
5) McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer's disease. Cochrane Database Syst Rev. 2014 ; 3 : CD009178.
PubMed
6) Wilt TJ, MacDonald R, Brasure M, et al. Pharmacologic treatment of insomnia disorder : an evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med. 2016 ; 3 : 1-10.
 
7) Shih HI, Lin CC, Tu YF, et al. An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population : a population based case-control study. Medicine. 2015 ; 94 : e809.
PubMed
8) Kashihara K, Nomura T, Maeda T, et al. Beneficial effects of ramelteon on rapid eye movement sleep behavior disorder associated with Parkinson's disease-results of a multicenter open trial. Intern Med. 2016 ; 55 : 231-6.
PubMed
9) Chen PL, Lee WJ, Sun WZ, et al. Risk of dementia in patients with insomnia and long-term use of hypnotics : a population-based retrospective cohort study. Plos One. 2012 ; 7 : e49113.
PubMed
10) Billioti de Gage S, Pariente A, Begaud B. Is there really a link between benzodiazepine use and the risk of dementia? Expert Opin Drug Saf. 2015 ; 14 : 733-47.
PubMed
11) American Geriatrics Society 2015 Updated beers criteria for potentially inappropriate medication use in older adults. By the American Geriatrics Society 2015 Beers Criteria Update expert panel. J Am Geriatr Soc. 2015 ; 63 : 2227-46.
 
12) Chang CM, Wu EC, Chen CY, et al. Psychotropic drugs and risk of motor vehicle accidents : a population-based case-control study. Br J Clin Pharmacol. 2013 ; 75 : 1125-33.
PubMed
13) van Strien AM, Koek HL, van Marum RJ, et al. Psychotropic medications, including short acting benzodiazepines, strongly increase the frequency of falls in elderly. Maturitas. 2013 ; 74 : 357-62.
PubMed
14) Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics and sedatives and risk of fractures : effects of half-life. Calcif Tissue Int. 2008 ; 82 : 34-43.
PubMed
15) Kao CH, Su LM, Su KP, et al. Benzodiazepine use possibly increases cancer risk". J Clin Psychiatry. 2012 ; 73 : e555-60.
 
16) Kripke DF, Langer RD, Kline E. Hypnotics' association with mortality or cancer : a matched cohort study. BMJ Open. 2012 ; 2 : e000850.
 
17) Billoti de Gage S, Begaud B, Bazin F, et al. Benzodiazepine use and risk of dementia : prospective population based study. BMJ. 2012 ; 345 : e6231.
 
18) Zhong GC, Yang Y, Zhang Y, et al. Association between benzodiazepine use and dementia : a meta-analysis. PLoS One. 2015 ; 10 : e0127836.
 
19) Ellul J, Archer N, Foy CML, et al. The effects of commonly prescribed drugs in patients with Alheimer's disease on the rate of deterioration. J Neurol Neurosurg Psychiatry. 2007 ; 78 : 233-9.
 
20) The Royal Australian College of General Practitioners. Benzodiazepines. In : Prescribing drugs of dependence in general practice, Part B. http://www.racgp.org.au/your-practice/guidelines/drugs-of-dependence-b/
 
P.82 掲載の参考文献
1) 仙波純一. 攻撃性と衝動性の評価と治療 攻撃性の前駆症状としての焦燥 焦燥の評価. 精神科治療学. 2006 ; 21 : 817-23.
 
2) 切目栄司, 辻井農亜, 松尾順子, 他. 高齢発症の気分障害の増加と認知症 高齢者における気分障害の診断と治療 器質因との関連. 臨床精神薬理. 2012 ; 15 : 1651-7.
 
3) 新里和弘. 高齢発症の気分障害の増加と認知症 高齢者の躁病・躁状態 鑑別の留意点と二次性躁病. 臨床精神薬理. 2012 ; 15 ; 1637-42.
 
4) Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2009 ; 8 : CD003945.
 
5) Yeh YC, Ouyang WC. Kaohsiung. Mood stabilizers for the treatment of behavioral and psychological symptoms of dementia : an update review. J Med Sci. 2012 ; 28 : 185-93.
 
6) Mendez M, Lim G. Seizures in elderly patients with dementia : epidemiology and management. Drugs Aging. 2003 ; 20 : 791-803.
PubMed
7) 立澤賢孝. 抗てんかん薬と精神科臨床 バルプロ酸ナトリウム. 精神科治療学. 2015 ; 30 : 1059-65.
 
8) 川畑信也. エキスパートの思考法. 認知症診療 (第12回) 周辺症状BPSDに対する向精神薬使用の実際 (2). 治療. 2013 ; 95 : 1107-11.
 
9) 伊藤ますみ. 抗てんかん薬と精神科臨床 Carbamazepine. 精神科治療学. 2015 ; 30 : 1053-7.
 
10) Shioya A, Saito Y, Arima K, et al. Neurodegenerative changes in patients with clinical history of bipolar disorders. Neuropathology. 2015 ; 35 : 245-53.
PubMed
11) Nagao S, Yokota O, Ikeda C, et al. Argyrophilic grain disease as a neurodegenerative substrate in late-onset schizophrenia and delusional disorders. Eur Arch Psychiatry Clin Neurosci. 2014 ; 264 : 317-31.
PubMed
P.92 掲載の参考文献
1) Suzuki T, Arai H, Iwasaki K, et al. A Japanese herbal medicine (Kami-Untan-To) in the treatment of Alzheimer's disease : A pilot study. Alzheim Res. 2001 ; 4 : 177-82.
 
2) Maruyama M, Tomita N, Iwasaki K, et al. Benefits of combining donepezil plus traditional Japanese herbal medicine on Alzheimer's disease : A 12-week observer-controlled trial. J Am Geriat Soc. 2006 ; 54 : 869-71.
 
3) Higashi K, Rakugi H, Yu H, et al. Effect of Kihito extract granules on cognitive function in patients with Alzheimer's-type dementia. Geriatr Gerontol Int. 2007 ; 7 : 245-51.
 
4) Iwasaki K, Kobayashi S, Chimura Y, et al. A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine "ba wei di huang wan" in the treatment of dementia. J Am Geriatr Soc. 2004 ; 52 : 1518-21.
PubMed
5) Hirokawa S, Nose M, Ishige A, et al. Effect of Hachimi-jio-gan on scopolamine-induced memory impairment and on acetylcholine content in rat brain. J Ethnopharmacol. 1996 ; 50 : 77-84.
 
6) 原敬二郎. 老人患者の情緒障害に対する抑肝散およびその加味方の効果について. 日本東洋医学雑誌. 1984 ; 35 : 49-54.
 
7) Iwasaki K, Satoh-Nakagawa T, Maruyama M, et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry. 2005 ; 66 : 248-52.
PubMed
8) Mizukami K, Asada T, Kinoshita T, et al. A randomized cross-over study of a traditional Japanese medicine (kampo), Yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. Int J Neuropsychopharmacol. 2009 ; 12 : 191-99.
PubMed
9) Okahara K, Ishida Y, Hayashi Y, et al. Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2010 ; 34 : 532-6.
PubMed
10) Matsuda Y, Kishi T, Shibayama H, et al. Yokukansan in the treatment of behavioral and psychological symptoms of dementia : a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol. 2013 ; 28 : 80-6.
PubMed
11) Teranishi M, Kurita M, Nishino S, et al. Efficacy and tolerability of risperidone, Yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia : a blinded, randomized trial. J Clin Psychopharmacol. 2013 ; 33 : 600-7.
 
12) Furukawa K, Tomita N, Uematsu D, et al. Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease. Geriatr Gerontol Int. 2017 ; 17 : 211-8.
PubMed
13) Iwasaki K, Kosaka K, Mori H, et al. Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of Yokukansan, a traditional Japanese medicine. Psychogeriatrics. 2012 ; 12 : 235-41.
PubMed
14) Nagata K, Yokoyama E, Yamazaki T, et al. Effects of yokukansan on behavioral and psychological symptoms of vascular dementia : An open-label trial. Phytomedicine. 2012 ; 19 : 524-8.
 
15) Kimura T, Takamatsu J. Pilot study of pharmacological treatment for frontotemporal dementia : effect of Yokukansan on behavioral symptoms. Psychiatry Clin Neurosci. 2010 ; 64 : 207-10.
PubMed
16) 水上勝義, 畑中公孝, 田中芳郎, 他. 認知症にみられる周辺症状に対する抑肝散の効果について. -17 自験例の検討から-. 漢方医学. 2009 ; 33 : 419-22.
 
17) Egashira N, Iwasaki K, Ishibashi A, et al. Repeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT) 2 A receptors in the prefrontal cortex. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2008 ; 32 : 1516-20.
PubMed
18) 五十嵐康, 川上善治, 菅野仁美, 他. 抑肝散のグルタミン酸トランスポーター賦活作用とセロトニン1A受容体パーシャルアゴニスト作用. 脳21. 2009 ; 12 : 409-15.
Medical*Online
19) 泉義雄. 痴呆症14例の暴力徘徊などの周辺陽性症状に対する抑肝散加陳皮半夏の改善効果. 漢方と最新治療. 2003 ; 12 : 352-6.
 
20) 宮澤仁朗. アルツハイマー型認知症に対する抑肝散加陳皮半夏の臨床的検討. 精神科. 2009 ; 14 : 535-42.
 
21) 馬込敦. 認知症に対する抑肝散加陳皮半夏の効果～東洋医学的観点も加えて～. 精神科. 2011 ; 18 : 108-14.
 
22) 荒木五郎. 黄連解毒湯の痴呆に対する効果の検討. 老年期痴呆. 1990 ; 4 : 110-7.
 
23) 大友英一, 東儀英夫, 小暮久也, 他. 脳血管障害に対するツムラ黄連解毒湯の臨床的有用性. Ca hopantenateを対照とした封筒法によるWell controlled study. Geriat Med. 1991 ; 29 : 121-51.
 
24) Iwasaki K, Maruyama M, Tomita N, et al. Effects of the traditional Chinese herbal medicine Yi-Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies. J Clin Psychiatry. 2005 ; 66 : 1612-3.
PubMed
25) Terasawa K, Shimada Y, Kita T, et al. Choto-san in the treatment of vascular dementia : a double-blind, placebo-controlled study. Phytomedicine. 1997 ; 4 : 15-22.
PubMed
26) Shinno H, Kamei M, Nakamura Y, et al. Successful treatment with Yi-Gan San for rapid eye movement sleep behavior disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008 ; 32 : 1749-51.
PubMed
27) 稲永和豊, 台之尊啓次郎, 二宮喜正, 他. 老年期認知障害の当帰芍薬散による治療効果-多施設共同研究-. Prog Med. 1996 ; 16 : 293-300.
 
28) Mizukami K. Kampo therapy and behavioral and psychological symptoms of dementia. Traditional & Kampo Medicine. 2014 ; 1 : 11-8.
 
P.103 掲載の参考文献
1) 領域別指針 10 泌尿器疾患 : 排尿障害 過活動膀胱. In : 日本老年医学会, 日本医療研究開発機構研究費・高齢者の薬物治療の安全性に関する研究研究班編. 高齢者の安全な薬物療法ガイドライン2015. 東京 : メジカルビュー社 ; 2015, p.120-3.
 
2) 山西友典. 臨床に役立つ Q&A 4. 排尿障害を起こしやすい薬剤について教えて下さい. Geriatric Medicine. 2014 ; 52 : 1101-5.
 
3) 日本神経学会 認知症疾患治療ガイドライン作成合同委員会編. 認知症疾患治療ガイドライン 2010. 東京 : 医学書院 ; 2010. p.136-8.
 
4) Sakakibara R, Uchiyama T, Yamanishi T, et al. Dementia and lower urinary dysfunction : with a reference to anticholinergic use in elderly population. Int J Urol. 2008 ; 15 : 778-88.
PubMed
P.111 掲載の参考文献
1) Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG) : a double-blind, placebo controlled trial. Lancet Neurol. 2008 ; 7 : 683-9.
PubMed
2) Levi Marpillat N, Macquin-Mavier I, Tropeano AI, et al. Antihypertensive classes, cognitive decline and incidence of dementia : a network meta-analysis. J Hypertens. 2013 ; 31 : 1073-82.
PubMed
3) Chang-Quan H, Hui W, Chao-Min W, et al. The association of antihypertensive medication use with risk of cognitive decline and dementia : a meta-analysis of longitudinal studies. Int J Clin Pract. 2011 ; 65 : 1295-305.
PubMed
4) Knopman DS, Penman AD, Catellier DJ, et al. Vascular risk factors and longitudinal changes on brain MRI : the ARIC study. Neurology. 2011 ; 76 : 1879-85.
PubMed
5) Verhaaren BF, Vernooij MW, de Boer R, et al. High blood pressure and cerebral white matter lesion progression in the general population. Hypertension. 2013 ; 61 : 1354-9.
PubMed
6) Appelman AP, Vincken KL, van der Graaf Y, et al. White matter lesions and lacunar infarcts are independently and differently associated with brain atrophy : the SMART-MR study. Cerebrovasc Dis. 2010 ; 29 : 28-35.
 
7) Hajjar I, Quach L, Yang F, et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood : the Cardiovascular Health Study. Circulation. 2011 ; 123 : 858-65.
PubMed
8) Waldstein SR, Rice SC, Thayer JF, et al. Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. Hypertension. 2008 ; 51 : 99-104.
PubMed
9) Nation DA, Wierenga CE, Delano-Wood L, et al. Elevated pulse pressure is associated with age-related decline in language ability. J Int Neuropsychol Soc. 2010 ; 16 : 933-8.
PubMed
10) Shah NS, Vidal JS, Masaki K, et al. Midlife blood pressure, plasma beta-amyloid, and the risk for Alzheimer disease : the Honolulu Asia Aging Study. Hypertension. 2012 ; 59 : 780-6.
PubMed
11) Rodrigue KM, Rieck JR, Kennedy KM, et al. Risk factors for beta-amyloid deposition in healthy aging : vascular and genetic effects. JAMA Neurol. 2013 ; 70 : 600-6.
PubMed
12) Schneider JA, Arvanitakis Z, Leurgans SE, et al. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009 ; 66 : 200-8.
PubMed
13) Li J, Wang YJ, Zhang M, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology. 2011 ; 76 : 1485-91.
 
14) Duron E, Rigaud AS, Dubail D, et al. Effects of antihypertensive therapy on cognitive decline in Alzheimer's disease. Am J Hypertens. 2009 ; 22 : 1020-4.
 
15) Inaba S, Iwai M, Tomono Y, et al. Exaggeration of focal cerebral ischemia in transgenic mice carrying human Renin and human angiotensinogen genes. Stroke. 2009 ; 40 : 597-603.
PubMed
16) Inaba S, Iwai M, Furuno M, et al. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension. 2009 ; 53 : 356-62.
PubMed
17) Ciobica A, Bild W, Hritcu L, et al. Brain renin-angiotensin system in cognitive function : pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg. 2009 ; 109 : 171-80.
PubMed
18) Starr JM, Whalley LJ, Deary IJ. The effects of antihypertensive treatment on cognitive function : results from the HOPE study. J Am Geriatr Soc. 1996 ; 44 : 411-5.
PubMed
19) Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003 ; 163 : 1069-75.
 
20) Sekizawa K, Jia YX, Ebihara T, et al. Role of substance P in cough. Pulm Pharmacol. 1996 ; 9 : 323-8.
PubMed
21) Iwata N, Tsubuki S, Takaki Y, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma : suppression leads to biochemical and pathological deposition. Nat Med. 2000 ; 6 : 143-50.
PubMed
22) Savaskan E, Hock C, Olivieri G, et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging. 2001 ; 22 : 541-6.
PubMed
23) Ohrui T, Tomita N, Sato-Nakagawa T, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology. 2004 ; 63 : 1324-5.
PubMed
24) Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem. 2005 ; 280 : 37644-50.
PubMed
25) Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population : prospective cohort analysis. BMJ. 2010 ; 340 : b5465.
 
26) Ito T, Yamakawa H, Bregonzio C, et al. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke. 2002 ; 33 : 2297-303.
PubMed
27) Benicky J, Sanchez-Lemus E, Honda M, et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology. 2011 ; 36 : 857-70.
PubMed
28) Zhu D, Shi J, Zhang Y, et al. Central angiotensin II stimulation promotes beta amyloid production in Sprague Dawley rats. PLoS One. 2011 ; 6 : e16037.
 
29) Danielyan L, Klein R, Hanson LR, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res. 2010 ; 13 : 195-201.
PubMed
30) Wang J, Ho L, Chen L, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 2007 ; 117 : 3393-402.
 
31) Tsukuda K, Mogi M, Iwanami J, et al. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension. 2009 ; 54 : 782-7.
PubMed
32) Washida K, Ihara M, Nishio K, et al. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion. Stroke. 2010 ; 41 : 1798-806.
PubMed
33) Trenkwalder P. The Study on COgnition and Prognosis in the Elderly (SCOPE) --recent analyses. J Hypertens Suppl. 2006 ; 24 : S107-14.
 
34) Kume K, Hanyu H, Sakurai H, et al. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. Geriatr Gerontol Int. 2012 ; 12 : 207-14.
PubMed
35) Furiya Y, Ryo M, Kawahara M, et al. Renin-angiotensin system blockers affect cognitive decline and serum adipocytokines in Alzheimer's disease. Alzheimers Dement. 2013 ; 9 : 512-8.
PubMed
36) Investigators O, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 ; 358 : 1547-59.
PubMed
37) Anderson C, Teo K, Gao P, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease : analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011 ; 10 : 43-53.
PubMed
38) Luong K, Nguyen LT. The role of beta-adrenergic receptor blockers in Alzheimer's disease : potential genetic and cellular signaling mechanisms. Am J Alzheimers Dis Other Demen. 2013 ; 28 : 427-39.
PubMed
39) Arrieta-Cruz I, Wang J, Pavlides C, et al. Carvedilol reestablishes long-term potentiation in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2010 ; 21 : 649-54.
 
40) Wang J, Ono K, Dickstein DL, et al. Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. Neurobiol Aging. 2011 ; 32 : 2321e1-12.
PubMed
41) Dobarro M, Orejana L, Aguirre N, et al. Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model. Neuropharmacology. 2013 ; 64 : 137-44.
 
42) Madden DJ, Blumenthal JA, Ekelund LG. Effects of beta-blockade and exercise on cardiovascular and cognitive functioning. Hypertension. 1988 ; 11 : 470-6.
PubMed
43) Fogari R, Mugellini A, Zoppi A, et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens. 2003 ; 17 : 781-5.
PubMed
44) Yasar S, Xia J, Yao W, et al. Antihypertensive drugs decrease risk of Alzheimer disease : Ginkgo Evaluation of Memory Study. Neurology. 2013 ; 81 : 896-903.
PubMed
45) Gelber RP, Ross GW, Petrovitch H, et al. Antihypertensive medication use and risk of cognitive impairment : the Honolulu-Asia Aging Study. Neurology. 2013 ; 81 : 888-95.
PubMed
46) Toescu EC, Verkhratsky A. The importance of being subtle : small changes in calcium homeostasis control cognitive decline in normal aging. Aging Cell. 2007 ; 6 : 267-73.
PubMed
47) Gorelick PB, Nyenhuis D, American Society of Hypertension Writing G, Materson BJ, Calhoun DA, Elliott WJ, et al. Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. J Am Soc Hypertens. 2012 ; 6 : 309-15.
 
48) Small DH, Gasperini R, Vincent AJ, et al. The role of Abeta-induced calcium dysregulation in the pathogenesis of Alzheimer's disease. J Alzheimers Dis. 2009 ; 16 : 225-33.
PubMed
49) Supnet C, Bezprozvanny I. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium. 2010 ; 47 : 183-9.
PubMed
50) Weiss JH, Pike CJ, Cotman CW. Ca2+channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture. J Neurochem. 1994 ; 62 : 372-5.
PubMed
51) Ueda K, Shinohara S, Yagami T, et al. Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+channels : a possible involvement of free radicals. J Neurochem. 1997 ; 68 : 265-71.
PubMed
52) Anekonda TS, Quinn JF, Harris C, et al. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol Dis. 2011 ; 41 : 62-70.
 
53) Copenhaver PF, Anekonda TS, Musashe D, et al. A translational continuum of model systems for evaluating treatment strategies in Alzheimer's disease : isradipine as a candidate drug. Dis Model Mech. 2011 ; 4 : 634-48.
PubMed
54) Trompet S, Westendorp RG, Kamper AM, et al. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging. 2008 ; 29 : 306-8.
PubMed
55) Scriabine A, van den Kerckhoff W. Pharmacology of nimodipine. A review. Ann N Y Acad Sci. 1988 ; 522 : 698-706.
PubMed
56) Sze KH, Sim TC, Wong E, et al. Effect of nimodipine on memory after cerebral infarction. Acta Neurol Scand. 1998 ; 97 : 386-92.
PubMed
57) Pantoni L, Bianchi C, Beneke M, et al. The Scandinavian Multi-Infarct Dementia Trial : a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci. 2000 ; 175 : 116-23.
 
58) Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998 ; 352 : 1347-51.
PubMed

Chapter III 各論

P.137 掲載の参考文献
1) Jones RW, Soininen H, Hanger K, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry. 2004 ; 19 : 58-67.
 
2) Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003 ; 20 : 777-89.
PubMed
3) Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract. 2002 ; 56 : 441-6.
 
4) Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin. 2005 ; 21 : 1317-27.
 
5) Kobayashi H, Ohnishi T, Nakagawa R, et al. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease : a Bayesian network meta-analysis. Int J Geriatr Psychiatry. 2016 ; 31 : 892-904.
PubMed
6) Shimabukuro J, Awata S, Matsuoka H. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease : a Bayesian network meta-analysis. Psychiatry and Clinical Neurosciences. 2005 ; 59 : 274-9.
 
7) Karttunen K, Karppi P, Hiltunen A, et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease. Int J Geriatr Psychiatry. 2011 ; 26 : 473-82.
PubMed
8) 馬場康彦. アルツハイマー病に対するガランタミンの臨床効果. Geriatric Medicine (老年医学). 2012 ; 50 : 339-42.
Medical*Online
9) Shimizu S, Kanetaka H, Hirose D, et al. Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease : a 12-month, randomized, and open-label trial. Dement Geriatr Cogn Disord. 2015 ; 5 : 135-46.
 
10) De Vriese C, Gregoire F, Lema-Kisoka R, et al. Ghrelin degradation by serum and tissue homogenates : identification of the cleavage sites. Endocrinology. 2004 ; 145 : 4997-5005.
PubMed
11) 角徳文, 森崇洋, 中山真美, 他. アルツハイマー病患者の食欲低下に対するリバスチグミンの効果に関する研究. 老年精神医学雑誌. 2016 ; 27巻増刊 II : 162.
 
12) 中村祐, 本間昭, 北村伸, 他. 新規NMDA受容体拮抗体であるメマンチン塩酸塩の中等度から高度アルツハイマー型認知症に対する第III相試験-有効性および安全性の検討-. 老年精神医学雑誌. 2011 ; 22 : 464-73.
 
13) Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil : a randomized controlled trial. JAMA. 2004 ; 291 : 317-24.
PubMed
14) Matsunaga S, Kishi T, Iwata N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease : a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2014 ; 18 pii : pyu115.
 
15) Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012 ; 366 : 893-903.
PubMed
16) Rabins PV, Blacker B, Rovner BW, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry. 2007 ; 164 : 5-56.
 
17) Arai H, Nakamura Y, Taguchi M. et al. Mortality risk in current and new antipsychotic Alzheimer's disease users : Large scale Japanese study. Alzheimers Dement. 2016 ; 12 : 823-30.
PubMed
18) Billioti de Gage S, Bgaud B, Bazin F, et al. Benzodiazepine use and risk of dementia : prospective population based study. BMJ. 2012 ; 354 : e6231.
 
19) Billioti de Gage S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer's disease : case-control study. BMJ. 2014 ; 349 : g5205.
 
20) Bateman RJ, Xiong C, Benzinger TL, at al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 ; 367 : 795-804.
 
21) Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009 ; 326 : 1005-7.
PubMed
22) Ju YE, McLeland JS, Toedebusch CD, et al. Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013 ; 70 : 587-93.
PubMed
23) Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment : clinical characterization and outcome. Arch Neurol. 1999 ; 56 : 303-8.
PubMed
24) Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 ; 7 : 270-9.
 
25) Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005 ; 352 : 2379-88.
PubMed
26) Ihara M, Nishino M, Taguchi A, et al. Cilostazol add-on therapy in patients with mild dementia receiving donepezil : a retrospective study. PLoS One. 2014 ; 9 : e89516.
PubMed
P.150 掲載の参考文献
1) Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia : diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993 ; 43 : 250-60.
PubMed
2) Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia : a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011 ; 42 : 2672-713.
PubMed
3) Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders : a VASCOG statement. Alzheimer Dis Assoc Disord. 2014 ; 28 : 206-18.
 
4) American Psychiatric Association Diagnostic and statistical manual of mental disorders : DSM-5. Washington, D. C. : American Psychiatric Association ; 2013.
PubMed
5) Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J Neurol Sci. 2007 ; 257 : 80-7.
PubMed
6) Ihara M, Yamamoto Y. Emerging evidence for pathogenesis of sporadic cerebral small vessel disease. Stroke. 2016 ; 47 : 554-60.
PubMed
7) Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013 ; 12 : 822-38.
PubMed
8) Yamamoto Y, Ihara M, Tham C, et al. Neuropathological correlates of temporal pole white matter hyperintensities in CADASIL. Stroke. 2009 ; 40 : 2004-11.
PubMed
9) Yakushiji Y, Nishiyama M, Yakushiji S, et al. Brain microbleeds and global cognitive function in adults without neurological disorder. Stroke. 2008 ; 39 : 3323-8.
PubMed
10) Poels MMF, Ikram MA, van der Lugt A, et al. Cerebral microbleeds are associated with worse cognitive function : the Rotterdam Scan Study. Neurology. 2012 ; 78 : 326-33.
PubMed
11) Tonomura S, Ihara M, Kawano T, et al. Intracerebral hemorrhage and deep microbleeds associated with cnm-positive Streptococcus mutans ; a hospital cohort study. Sci Rep. 2016 ; 6 : 20074.
PubMed
12) Li N-C, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population : prospective cohort analysis. BMJ. 2010 ; 340 : b5465.
 
13) Washida K, Ihara M, Nishio K, et al. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion. Stroke. 2010 ; 41 : 1798-806.
PubMed
14) Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016 ; 374 : 1321-31.
 
15) Meneilly GS, Cheung E, Tessier D, et al. The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol. 1993 ; 48 : M117-21.
PubMed
16) Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment : prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366 : 1267-78.
PubMed
17) Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia : the Cardiovascular Health Study. Arch Neurol. 2005 ; 62 : 1047-51.
PubMed
18) Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition : a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013 ; 88 : 1213-21.
 
19) Ravaglia G, Forti P, Lucicesare A, et al. Physical activity and dementia risk in the elderly : findings from a prospective Italian study. Neurology. 2008 ; 70 : 1786-94.
PubMed
20) Perez L, Heim L, Sherzai A, et al. Nutrition and vascular dementia. J Nutr Health Aging. 2012 ; 16 : 319-24.
PubMed
21) Malouf M, Grimley EJ, Areosa SA. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane database Syst Rev. 2003 ; : CD004514.
 
22) Beydoun MA, Beydoun HA, Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes : a systematic review and meta-analysis. Obes Rev. 2008 ; 9 : 204-18.
PubMed
23) Price JF, Stewart MC, Deary IJ, et al. Low dose aspirin and cognitive function in middle aged to elderly adults : randomised controlled trial. BMJ. 2008 ; 337 : a1198.
PubMed
24) Sturmer T, Glynn RJ, Field TS, et al. Aspirin use and cognitive function in the elderly. Am J Epidemiol. 1996 ; 143 : 683-91.
PubMed
25) Meyer JS, Rogers RL, McClintic K, et al. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc. 1989 ; 37 : 549-55.
PubMed
26) Douiri A, McKevitt C, Emmett ES, et al. Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation. 2013 ; 128 : 1341-8.
PubMed
27) Diener H-C, Sacco RL, Yusuf S, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRo-FESS) trial : a double-blind, active and placebo-controlled study. Lancet Neurol. 2008 ; 7 : 875-84.
 
28) Pearce LA, McClure LA, Anderson DC, et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke : a secondary analysis from the SPS3 randomised trial. Lancet Neurol. 2014 ; 13 : 1177-85.
PubMed
29) Rinnoci V, Nannucci S, Valenti R, et al. Cerebral hemorrhages in CADASIL : report of four cases and a brief review. J Neurol Sci. 2013 ; 330 : 45-51.
 
30) Jacobs V, Woller SC, Stevens S, et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm. 2014 ; 11 : 2206-13.
PubMed
31) Keage HAD, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia : a systematic review. BMC Neurol. 2009 ; 9 : 3.
PubMed
32) Arima H, Anderson C, Omae T, et al. Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy : the PROGRESS trial. Stroke. 2012 ; 43 : 1675-7.
PubMed
33) Piazza F, Greenberg SM, Savoiardo M, et al. Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation : Implications for Amyloid-Modifying Therapies. Ann Neurol. 2013 ; 73 : 449-58.
 
34) Kloppenborg RP, Richard E, Sprengers MES, et al. Steroid responsive encephalopathy in cerebral amyloid angiopathy : a case report and review of evidence for immunosuppressive treatment. J Neuroinflammation. 2010 ; 7 : 18.
PubMed
35) Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane database Syst Rev. 2004 ; CD004395.
PubMed
36) Dichgans M, Markus HS, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive impairment : a randomised double-blind trial in CADASIL. Lancet Neurol. 2008 ; 7 : 310-8.
PubMed
37) Auchus AP, Brashear HR, Salloway S, et al. Galantamine treatment of vascular dementia : a randomized trial. Neurology. 2007 ; 69 : 448-58.
PubMed
38) McGuinness B, O'Hare J, Craig D, et al. Cochrane review on "Statins for the treatment of dementia". Int J Geriatr Psychiatry. 2013 ; 28 : 119-26.
PubMed
39) Birks J, McGuinness B, Craig D. Rivastigmine for vascular cognitive impairment. Cochrane database Syst Rev. 2013 ; 5 : CD004744.
PubMed
40) Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia : a randomized, placebo-controlled trial (MMM 300). Stroke. 2002 ; 33 : 1834-9.
PubMed
41) Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002 ; 17 : 297-305.
PubMed
42) Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults : a randomized trial. JAMA. 2009 ; 302 : 2663-70.
PubMed
43) Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003 ; 64 : 134-43.
 
P.164 掲載の参考文献
1) McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies : third report of the DLB consortium. Neurology. 2005 ; 65 : 1863-72.
PubMed
2) Fujiwara H, Hasegawa M, Dohmae N, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002 ; 4 : 160-4.
PubMed
3) Takahashi M, Kanuka H, Fujiwara H, et al. Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci Lett. 2003 ; 336 : 155-8.
PubMed
4) Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003 ; 24 : 197-211
 
5) Masuda-Suzukake M, Nonaka T, Hosokawa M, et al. Pathological alpha-synuclein propagates through neural networks. Acta Neuropathol Commun. 2014 ; 2 : 88.
PubMed
6) Yoshita M, Arai H, Arai H, et al. Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies : a multicenter study. PLoS One. 2015 ; 10 : e0120540.
PubMed
7) American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-5. 5th ed. Washington, DC : American Psychiatric Association, 2013.
 
8) Ballard C, Aarsland D, Francis P, et al. Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies : pathophysiology, clinical features, and pharmacological management. Drugs Aging. 2013 ; 30 : 603-11.
PubMed
9) Walker Z, Possin KL, Boeve BF, et al. Lewy body dementias. Lancet. 2015 ; 386 : 1683-97.
 
10) Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004 ; 351 : 2509-18.
PubMed
11) Mori E, Ikeda M, Kosaka K and the Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies : a randomized, placebo-controlled trial. Ann Neurol. 2012 ; 72 : 41-52.
 
12) Ikeda M, Mori E, Matsuo K, et al. Donepezil for dementia with Lewy bodies : a randomized, placebo-controlled, confi rmatory phase III trial. Alzheimers Res Ther. 2015 ; 7 : 4.
 
13) Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia : a randomized, double-blind efficacy and safety study. Mov Disord. 2012 ; 27 : 1230-8.
PubMed
14) McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies : a randomised, double-blind, placebo-controlled international study. Lancet. 2000 ; 356 : 2031-6.
 
15) Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology. 2009 ; 73 : 273-8.
PubMed
16) Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies : systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015 ; 86 : 135-43.
PubMed
17) Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies : a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 ; 9 : 969-77.
PubMed
18) Kurlan R, Cummings J, Raman R, Thal L, and the Alzheimer's Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007 ; 68 : 1356-63.
PubMed
19) Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis : a randomised, placebo-controlled phase 3 trial. Lancet. 2014 ; 383 : 533-40.
PubMed
20) "Press Announcements-FDA approves first drug to treat hallucinations and delusions associated with Parkinson's disease". U. S. Food and Drug Administration. Retrieved 1 May 2016 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498442.htm
 
21) McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies : a randomised, double-blind, placebo-controlled international study. Lancet. 2000 ; 356 : 2031-6.
 
22) Ikeda M, Mori E, Kosaka K, et al, and the Donepezil-DLB Study Investigators. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies : results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord. 2013 ; 36 : 229-41.
 
23) Richard IH, McDermott MP, Kurlan R, et al, and the SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012 ; 78 : 1229-36.
 
24) Trotti LM, Bliwise DL. Treatment of the sleep disorders associated with Parkinson's disease. Neurotherapeutics. 2014 ; 11 : 68-77.
PubMed
25) Boeve BF, Silber MH, Ferman TJ, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013 ; 14 : 754-62.
PubMed
26) McCarter SJ, Boswell CL, St Louis EK, et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med. 2013 ; 14 : 237-42.
PubMed
27) Larsson V, Aarsland D, Ballard C, et al. The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry. 2010 ; 25 : 1030-8.
PubMed
28) Onofrj M, Luciano AL, Thomas A, et al. Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology. 2003 ; 60 : 113-5.
PubMed
29) Molloy S, McKeith IG, O'Brien JT, et al. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005 ; 76 : 1200-3.
PubMed
30) Horimoto Y, Matsumoto M, Akatsu H, et al. Autonomic dysfunctions in dementia with Lewy bodies. J Neurol. 2003 ; 250 : 530-3.
PubMed
31) Woitalla D, Kassubek J, et al. Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch : a non-interventional prospective multicenter trial. Parkinsonism & Related Disorders. 2015 ; 21 : 199-204.
PubMed
32) Orme S, Morris V, Gibson W, et al. Managing urinary incontinence in patients with dementia : pharmacological treatment options and considerations. Drugs Aging. 2015 ; 32 : 559-67.
PubMed
33) Sakakibara R, Uchiyama T, Yoshiyama M, et al. Preliminary communication : urodynamic assessment of donepezil hydrochloride in patients with Alzheimer's disease. Neurourol Urodyn. 2005 ; 24 : 273-5.
PubMed
P.176 掲載の参考文献
1) 新井哲明. 認知症性疾患の病理・分子対応. Cogn Dement. 2013 ; 1 : 48-55.
 
2) Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011 ; 76 : 1006-14.
PubMed
3) Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011 ; 134 : 2456-77.
PubMed
4) Shinagawa S, Nakajima S, Plitman E, et al. Non-pharmacological management for patients with frontotemporal dementia : a systematic review. J Alzheimers Dis. 2015 ; 45 : 283-93.
PubMed
5) 繁信和恵. 前頭側頭型認知症の非薬物療法-作業療法的アプローチによる取り組み. In : 池田学. 専門医のための精神科臨床リュミエール 12 前頭側頭型認知症の臨床. 東京 : 中山書店 ; 2010. p.66-74.
 
6) Yokota O, Fujisawa Y, Takahashi J, et al. Effects of group-home care on behavioral symptoms, quality of life, and psychotropic drug use in patients with frontotemporal dementia. J Am Med Dir Assoc. 2006 ; 7 : 335-7.
PubMed
7) 小森憲治郎, 石川智久, 繁信和恵, 他. Semantic dementia例に対する語彙再獲得訓練. In : 認知リハビリテーション研究会, 認知リハビリテーション 2004. 東京 : 新興医学出版社 ; 2004. p.86-94.
 
8) Tippett DC, Hillis AE, Tsapkini K. Treatment of Primary Progressive Aphasia. Curr Treat Options Neurol. 2015 ; 17 : 362.
PubMed
9) 越部裕子. 実録-様々な前頭側頭葉変性症にみられる言語症状. 認知神経科学. 2016 ; 18 : 24-9.
 
10) Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia : past, present, and future. J Neurochem. 2016 (10.1111/jnc. 13640).
 
11) 品川俊一郎, 谷田部裕介, 繁信和恵他. 本邦におけるFTD に対するoff-label処方の実態について. Dementia Japan. 2015 ; 29 : 78-85.
 
12) Kimura T, Hayashida H, Furukawa H, et al. Pilot study of pharmacological treatment for frontotemporal dementia : effect of Yokukansan on behavioral symptoms. Psychiatry Clin Neurosci. 2010 ; 64 : 207-10.
PubMed
13) Finger EC, MacKinley J, Blair M, et al. Oxytocin for frontotemporal dementia : a randomized dose-finding study of safety and tolerability. Neurology. 2015 ; 84 : 174-81.
PubMed
P.194 掲載の参考文献
1) Braak H, Rub U, Sandmann-Keil D, et al. Parkinson's disease : affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol. 2000 ; 99 : 489-95.
PubMed
2) Braak H, Rub U, Gai WP, et al. Idiopathic Parkinson's disease : possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna). 2003 ; 110 : 517-36.
PubMed
3) Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964 ; 10 : 333-59.
PubMed
4) Albert ML, Feldman RG, Willis AL. The'subcortical dementia'of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1974 ; 37 : 121-30.
PubMed
5) Dubois B, Slachevsky A, Pillon B, et al. "Applause sign" helps to discriminate PSP from FTD and PD. Neurology. 2005 ; 64 : 2132-3.
PubMed
6) Grafman J, Litvan I, Gomez C, et al. Frontal lobe function in progressive supranuclear palsy. Arch Neurol. 1990 ; 47 : 553-8.
PubMed
7) Paviour DC, Winterburn D, Simmonds S, et al. Can the frontal assessment battery (FAB) differentiate bradykinetic rigid syndromes? Relation of the FAB to formal neuropsychological testing. Neurocase. 2005 ; 11 : 274-82.
PubMed
8) Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol. 1968 ; 18 : 20-33.
PubMed
9) Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain. 1989 ; 112 (Pt 5) : 1171-92.
 
10) Pillon B, Blin J, Vidailhet M, et al. The neuropsychological pattern of corticobasal degeneration : comparison with progressive supranuclear palsy and Alzheimer's disease. Neurology. 1995 ; 45 : 1477-83.
PubMed
11) Dubois B, Slachevsky A, Litvan I, et al. The FAB : a Frontal Assessment Battery at bedside. Neurology. 2000 ; 55 : 1621-6.
PubMed
12) 森松光紀, 根来清. 症候学-とくに暫定臨床診断基準によるCBD症例の全国施設調査. 臨床神経. 2002 ; 42 : 1150-3.
 
13) 谷口彰, 成田有吾, 内藤寛, 他. 厚生労働省特定疾患治療研究事業臨床調査個人票の集計結果からみたパーキンソン病患者の現況. 臨床神経. 2008 ; 48 : 106-13.
 
14) Osaki Y, Morita Y, Kuwahara T, et al. Prevalence of Parkinson's disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand. 2011 ; 124 : 182-7.
 
15) Daniel TM. The origins and precolonial epidemiology of tuberculosis in the Americas : can we figure them out? Int J Tuberc Lung Dis. 2000 ; 4 : 395-400.
PubMed
16) Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy : Richardson's syndrome and PSP-parkinsonism. Brain. 2005 ; 128 (Pt 6) : 1247-58.
 
17) Williams DR, Holton JL, Strand K, et al. Pure akinesia with gait freezing : a third clinical phenotype of progressive supranuclear palsy. Mov Disord. 2007 ; 22 : 2235-41.
PubMed
18) Knibb JA, Woollams AM, Hodges JR, et al. Making sense of progressive non-fluent aphasia : an analysis of conversational speech. Brain. 2009 ; 132 (Pt 10) : 2734-46.
 
19) Josephs KA, Boeve BF, Duffy JR, et al. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase. 2005 ; 11 : 283-96.
PubMed
20) Kanazawa M, Shimohata T, Toyoshima Y, et al. Cerebellar involvement in progressive supranuclear palsy : A clinicopathological study. Mov Disord. 2009 ; 24 : 1312-8.
PubMed
21) Shimohata T, Kanazawa M, Yoshida M, et al. Clinical and imaging findings of progressive supranuclear palsy with predominant cerebellar ataxia. Mov Disord. 2016 ; 31 : 760-2.
PubMed
22) Tsuboi Y, Josephs KA, Boeve BF, et al. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord. 2005 ; 20 : 982-8.
PubMed
23) Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain. 2007 ; 130 (Pt 6) : 1552-65.
 
24) Schrag A, Selai C, Quinn N, et al. Measuring quality of life in PSP : the PSP-QoL. Neurology. 2006 ; 67 : 39-44.
PubMed
25) Bak TH, Hodges JR. Corticobasal degeneration : clinical aspects. Handb Clin Neurol. 2008 ; 89 : 509-21.
PubMed
26) Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) : report of the NINDS-SPSP international workshop. Neurology. 1996 ; 47 : 1-9.
 
27) Mathew R, Bak TH, Hodges JR. Diagnostic criteria for corticobasal syndrome : a comparative study. J Neurol Neurosurg Psychiatry. 2012 ; 83 : 405-10.
PubMed
28) Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013 ; 80 : 496-503.
PubMed
29) Kraemmer J, Kovacs GG, Perju-Dumbrava L, et al. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord. 2014 ; 29 : 1767-73.
PubMed
30) Orimo S, Ozawa E, Nakade S, et al. (123) I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999 ; 67 : 189-94.
PubMed
31) Braune S, Reinhardt M, Schnitzer R, et al. Cardiac uptake of [123I] MIBG separates Parkinson's disease from multiple system atrophy. Neurology. 1999 ; 53 : 1020-5.
PubMed
32) Filippi L, Manni C, Pierantozzi M, et al. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease : a SPECT semiquantitative study. Nucl Med Commun. 2006 ; 27 : 381-6.
PubMed
33) Cilia R, Rossi C, Frosini D, et al. Dopamine transporter SPECT imaging in corticobasal syndrome. PLoS One. 2011 ; 6 : e18301.
PubMed
34) Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006 ; 66 : 41-8.
PubMed
35) Litvan I. Update on epidemiological aspects of progressive supranuclear palsy. Mov Disord. 2003 ; 18 Suppl 6 : S43-50.
 
36) Vanacore N, Bonifati V, Colosimo C, et al. Epidemiology of progressive supranuclear palsy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. Neurol Sci. 2001 ; 22 : 101-3.
 
37) Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999 ; 8 : 711-5.
PubMed
38) Di Maria E, Tabaton M, Vigo T, et al. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol. 2000 ; 47 : 374-7.
PubMed
39) Houlden H, Baker M, Morris HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001 ; 56 : 1702-6.
 
40) Pittman AM, Myers AJ, Abou-Sleiman P, et al. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet. 2005 ; 42 : 837-46.
PubMed
41) Rademakers R, Melquist S, Cruts M, et al. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet. 2005 ; 14 : 3281-92.
PubMed
42) Hoglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011 ; 43 : 699-705.
PubMed
43) Li Y, Chen JA, Sears RL, et al. An epigenetic signature in peripheral blood associated with the haplotype on 17q21.31, a risk factor for neurodegenerative tauopathy. PLoS Genet. 2014 ; 10 : e1004211.
 
44) 濱田恭子, 岸本利一郎, 湯浅龍彦. 進行性核上性麻痺に対する3系統神経伝達物質補充療法による運動および認知機能の改善. 日本早期認知症学会誌. 2015 ; 8 : 56-65.
Medical*Online
45) Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders : the NNIPPS study. Brain. 2009 ; 132 (Pt 1) : 156-71.
 
46) Liepelt I, Gaenslen A, Godau J, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy : Clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 2010 ; 6 : 70-4.
PubMed
47) Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival : a clinicopathological study. J Neurol Neurosurg Psychiatry. 1996 ; 60 : 615-20.
PubMed
48) dell'Aquila C, Zoccolella S, Cardinali V, et al. Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients. Parkinsonism Relat Disord. 2013 ; 19 : 980-5.
 
49) Tolosa E, Litvan I, Hoglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014 ; 29 : 470-8.
PubMed
50) Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy : a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 ; 13 : 676-85.
PubMed
51) Apetauerova D, Scala SA, Hamill RW, et al. CoQ10 in progressive supranuclear palsy : A randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm. 2016 ; 3 : e266.
PubMed
52) Golbe LI, Davis PH, Schoenberg BS, et al. Prevalence and natural history of progressive supranuclear palsy. Neurology. 1988 ; 38 : 1031-4.
PubMed
53) Wermuth L, Joensen P, Bunger N, et al. High prevalence of Parkinson's disease in the Faroe Islands. Neurology. 1997 ; 49 : 426-32.
PubMed
54) Chio A, Magnani C, Schiffer D. Prevalence of Parkinson's disease in Northwestern Italy : comparison of tracer methodology and clinical ascertainment of cases. Mov Disord. 1998 ; 13 : 400-5.
PubMed
55) Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy : a cross-sectional study. Lancet. 1999 ; 354 : 1771-5.
PubMed
56) Nath U, Ben-Shlomo Y, Thomson RG, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain. 2001 ; 124 (Pt 7) : 1438-49.
 
57) Kawashima M, Miyake M, Kusumi M, et al. Prevalence of progressive supranuclear palsy in Yonago, Japan. Mov Disord. 2004 ; 19 : 1239-40.
 
58) Takigawa H, Kitayama M, Wada-Isoe K, et al. Prevalence of Progressive Supranuclear Palsy in Yonago : Change throughout a Decade. Brain Bhav. 2016 ; 6 : e00557.
 
59) Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology. 1990 ; 40 : 1203-12.
PubMed
60) Rinne JO, Lee MS, Thompson PD, et al. Corticobasal degeneration. A clinical study of 36 cases. Brain. 1994 ; 117 (Pt 5) : 1183-96.
 
61) Schneider JA, Watts RL, Gearing M, et al. Corticobasal degeneration : neuropathologic and clinical heterogeneity. Neurology. 1997 ; 48 : 959-69.
PubMed
62) Wenning GK, Litvan I, Jankovic J, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry. 1998 ; 64 : 184-9.
PubMed
P.215 掲載の参考文献
1) American Psychiatric Association, 日本精神神経学会監修. DSM-5 精神疾患の診断・統計マニュアル. 東京 : 医学書院 ; 2014.
 
2) Trzepacz PT, Franco JG, Meagher DJ, et al. Phenotype of subsyndromal delirium using pooled multicultural Delirium Rating Scale-Revised-98 data. J Psychosom Res. 2012 ; 73 : 10-7.
 
3) Catic AG. Identification and management of in-hospital drug-induced delirium in older patients. Drugs Aging. 2011 ; 28 : 737-48.
PubMed
4) Marcantonio ER. Postoperative delirium : a 76-year-old woman with delirium following surgery. JAMA. 2012 ; 308 : 73-81.
PubMed
5) Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion : the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990 ; 113 : 941-8.
 
6) Trzepacz PT, Baker RW, Greenhouse J. A symptom rating scale for delirium. Psychiatry Res. 1988 ; 23 : 89-97.
PubMed
7) Trzepacz PT, Mittal D, Torres R, et al. Validation of the Delirium Rating Scale-revised-98 : comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatry Clin Neurosci. 2001 ; 13 : 229-42.
PubMed
8) Trzepacz Paula T, 岸泰宏, 保坂隆, 他. 日本語版せん妄評価尺度 98年改訂版. 精神医学. 2001 ; 43 : 1365-71.
 
9) Kato M, Kishi Y, Okuyama T, et al. Japanese version of the Delirium Rating Scale, Revised-98 (DRS-R98-J) : reliability and validity. Psychosomatics. 2010 ; 51 : 425-31.
PubMed
10) Breitbart W, Rosenfeld B, Roth A, et al. The Memorial Delirium Assessment Scale. J Pain Symptom Manage. 1997 ; 13 : 128-37.
PubMed
11) Matsuoka Y, Miyake Y, Arakaki H, et al. Clinical utility and validation of the Japanese version of Memorial Delirium Assessment Scale in a psychogeriatric inpatient setting. Gen Hosp Psychiatry. 2001 ; 23 : 36-40.
 
12) 町田いづみ, 青木孝之, 上月清司, 他. せん妄スクリーニング・ツール (DST) の作成. 総合病院精神医学. 2003 ; 15 : 150-5.
 
13) Neelon VJ, Champagne MT, Carlson JR, et al. The NEECHAM Confusion Scale : construction, validation, and clinical testing. Nurs Res. 1996 ; 45 : 324-30.
PubMed
14) Rapp CG, Wakefield B, Kundrat M, et al. Acute confusion assessment instruments : clinical versus research usability. Appl Nurs Res. 2000 ; 13 : 37-45.
PubMed
15) Bryson GL, Wyand A, Wozny D, et al. The clock drawing test is a poor screening tool for postoperative delirium and cognitive dysfunction after aortic repair. Can J Anaesth. 2011 ; 58 : 267-74.
PubMed
16) Grover S, Kate N. Assessment scales for delirium : A review. World J Psychiatry. 2012 ; 2 : 58-70.
PubMed
17) Wong CL, Holroyd-Leduc J, Simel DL, et al. Does this patient have delirium? value of bedside instruments. JAMA. 2010 ; 304 : 779-86.
PubMed
18) Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients : validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001 ; 29 : 1370-9.
PubMed
19) Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale : validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002 ; 166 : 1338-44.
PubMed
20) Bergeron N, Dubois MJ, Dumont M, et al. Intensive Care Delirium Screening Checklist : evaluation of a new screening tool. Intensive Care Med. 2001 ; 27 : 859-64.
PubMed
21) Kean J, Trzepacz PT, Murray LL, et al. Initial validation of a brief provisional diagnostic scale for delirium. Brain Inj. 2010 ; 24 : 1222-30.
PubMed
21) Trzepacz PT, Sclabassi RJ, Van Thiel DH. Delirium : a subcortical phenomenon? J Neuropsychiatry Clin Neurosci. 1989 ; 1 : 283-90.
PubMed
22) van Munster BC, de Rooij SE, Yazdanpanah M, et al. The association of the dopamine transporter gene and the dopamine receptor 2 gene with delirium, a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2010 ; 153B : 648-55.
PubMed
23) Eitan N, Levin Y, Ben-Artzi E, et al. Effects of antipsychotic drugs on memory functions of schizophrenic patients. Acta Psychiatr Scand. 1992 ; 85 : 74-6.
PubMed
24) Jacobsen FM, Sack DA, James SP. Delirium induced by verapamil. Am J Psychiatry. 1987 ; 144 : 248.
PubMed
25) Dimsdale JE, Newton RP, Joist T. Neuropsychological side effects of beta-blockers. Arch Intern Med. 1989 ; 149 : 514-25.
PubMed
26) Eisendrath SJ, Sweeney MA. Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations. Am J Psychiatry. 1987 ; 144 : 506-7.
PubMed
27) Saravay SM, Marke J, Steinberg MD, et al. "Doom anxiety" and delirium in lidocaine toxicity. Am J Psychiatry. 1987 ; 144 : 159-63.
PubMed
28) Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med. 1984 ; 101 : 92-104.
PubMed
29) Someya T, Shibasaki M, Noguchi T, et al. Haloperidol metabolism in psychiatric patients : importance of glucuronidation and carbonyl reduction. J Clin Psychopharmacol. 1992 ; 12 : 169-74.
PubMed
30) 倉田明子, 和田健. B. 予防 1. 非薬物的アプローチ. In : 日本総合病院精神医学会 せん妄指針改訂班編. せん妄の臨床指針 [せん妄の治療指針 第2版]. 東京 : 星和書店 ; 2015. p.33-46, p.64-65.
 
31) Wang W, Li HL, Wang DX, et al. Haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery : a randomized controlled trial. Crit Care Med. 2012 ; 40 : 731-9.
 
32) Prakanrattana U, Prapaitrakool S. Efficacy of risperidone for prevention of postoperative delirium in cardiac surgery. Anaesth Intensive Care. 2007 ; 35 : 714-9.
PubMed
33) Hakim SM, Othman AI, Naoum DO. Early treatment with risperidone for subsyndromal delirium after on-pump cardiac surgery in the elderly : a randomized trial. Anesthesiology. 2012 ; 116 : 987-97.
PubMed
34) Larsen KA, Kelly SE, Stern TA, et al. Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients : a randomized, controlled trial. Psychosomatics. 2010 ; 51 : 409-18.
PubMed
35) Leung JM, Sands LP, Rico M, et al. Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients. Neurology. 2006 ; 67 : 1251-3.
PubMed
36) Sultan SS. Assessment of role of perioperative melatonin in prevention and treatment of postoperative delirium after hip arthroplasty under spinal anesthesia in the elderly. Saudi J Anaesth. 2010 ; 4 : 169-73.
PubMed
37) Al-Aama T, Brymer C, Gutmanis I, et al. Melatonin decreases delirium in elderly patients : a randomized, placebo-controlled trial. Int J Geriatr Psychiatry. 2011 ; 26 : 687-94.
PubMed
38) Hatta K, Kishi Y, Wada K, et al. Preventive effects of ramelteon on delirium : a randomized placebo-controlled trial. JAMA Psychiatry. 2014 ; 71 : 397-403.
PubMed
39) 八田耕太郎. C. 救急対応. In : 日本総合病院精神医学会 せん妄指針改訂班編. せん妄の臨床指針 [せん妄の治療指針 第2版]. 東京 : 星和書店 ; 2015. p.69-84.
 
40) Heymann A, Radtke F, Schiemann A, et al. Delayed treatment of delirium increases mortality rate in intensive care unit patients. J Int Med Res. 2010 ; 38 : 1584-95.
PubMed
41) 奥村泰之, 八田耕太郎. D. 治療. In : 日本総合病院精神医学会 せん妄指針改訂班編. せん妄の臨床指針 [せん妄の治療指針 第2版]. 東京 : 星和書店 ; 2015. p.85-111.
 
42) Kishi T, Hirota T, Matsunaga S, et al. Antipsychotic medications for the treatment of delirium : a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2016 ; 87 : 767-74.
PubMed
43) Hatta K, Kishi Y, Wada K, et al. Antipsychotics for delirium in the general hospital setting in consecutive 2453 inpatients : a prospective observational study. Int J Geriatr Psychiatry. 2014 ; 29 : 253-62.
PubMed
44) 厚生労働省. 平成23年9月28日厚生労働省保険局医療課長通知 (保医発0928 第1号). 2011.
 

書評

最近チェックした商品履歴

Loading...